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ABSTRACT
Objectives To evaluate whether the association between
migraine with aura and increased risk of cardiovascular
disease is modified by vascular risk groups as measured
by the Framingham risk score for coronary heart disease.
Design Prospective cohort study.
Setting Women’s health study, United States.
Participants 27519 women who were free from
cardiovascular disease at baseline with available
information on the Framingham risk score and migraine
status.
Main outcome measures Time to major cardiovascular
disease event (non-fatal myocardial infarction, non-fatal
ischaemic stroke, death from ischaemic cardiovascular
disease), myocardial infarction, and ischaemic stroke.
ResultsAtbaseline,3577(13.0%)womenreportedactive
migraine, of whom 1418 (39.6%) reported migraine with
aura. During 11.9 years of follow-up, there were 697
cardiovascular disease events. We stratified participants
basedon10yearriskofcoronaryheartdiseaseestimated
from the Framingham risk score (≤1%, 2-4%, 5-9%, and
≥10%). Compared with women without migraine, the age
adjustedhazardratiosinwomenwithactivemigrainewith
aurawere 1.93(95% confidenceinterval 1.45to 2.56) for
major cardiovascular disease, 1.80 (1.16 to 2.79) for
ischaemic stroke, and 1.94 (1.27 to 2.95) for myocardial
infarction. When stratified by Framingham risk score, the
association between migraine with aura and major
cardiovascular disease was strongest in the lowest risk
scoregroup.Therewasadiametricassociationpatternfor
ischaemic stroke and myocardial infarction. Compared
with women without migraine, the age adjusted hazard
ratios in women who reported migraine with aura in the
lowest Framingham risk score group were 3.88 (1.87 to
8.08) for ischaemic stroke and 1.29 (0.40 to 4.21) for
myocardial infarction. Hazard ratios in women with
migraine with aura in the highest Framingham risk score
group were 1.00 (0.24 to 4.14) for ischaemic stroke and
3.34(1.50to7.46)formyocardialinfarction.Womenwith
migraine without aura were not at increased risk of
ischaemic stroke or myocardial infarction in any of the
Framingham risk score groups.
Conclusion The association between migraine with aura
andcardiovascular diseasevariesbyvascularriskstatus.
Informationonhistoryofmigraineandvascularriskstatus
mighthelptoidentifywomenatincreasedriskforspecific
future cardiovascular disease events.
Trial registration Clinical trials NCT00000479.
INTRODUCTION
Migraine is a common primary headache disorder
characterised by severe, pulsating, mostly unilateral
headaches accompanied by vomiting, nausea, and
autonomic dysfunctions. In the United States alone,
about18%ofthefemalepopulationand6%ofthemale
population have migraine headaches.
1 Some people
experience transient neurological symptoms before or
during the headache that are most often visual, such as
seeingzigzaglinesorflashspots,butmightalsoinclude
sensory or motor symptoms. These symptoms are
known as migraine aura. The pathophysiology of
migraine involves the neuronal system as well as the
cranialvascularsystem.
2Peripheralarteriescanalsobe
affected in patients with migraine.
34
Migraine with aura is associated with an increased
risk of ischaemic stroke,
5-8 angina,
910 and other
ischaemic vascular events, including myocardial
infarction.
1112 It remains unclear which mechanisms
link migraine with vascular events and whether the
biological mechanisms leading to ischaemic stroke
differ from the mechanisms leading to myocardial
infarction.
Migraine with aura has also been associated with an
unfavourablecardiovascularriskprofileandincreased
10 year predicted risk of coronary heart disease based
on the Framingham risk score.
13 This has led to
speculation about whether the increased risk of
ischaemic vascular events among patients with
migraine with aura is partly caused by this increased
prevalence of cardiovascular risk factors. Several
observations question this hypothesis. Firstly, the
association between migraine and ischaemic vascular
events is independent of many cardiovascular risk
factors.
1112 Secondly, the increased risk of ischaemic
stroke is more apparent among individuals without
cardiovascular risk factors,
578 with the exception of
smoking
1415oruseoforalcontraceptives,
61415orboth.
8
A potential association between migraine and
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vascularriskstatusisimportantforcliniciansasitmight
help to identify individuals at increased risk of future
cardiovascular disease events. We evaluated whether
theassociationbetweenmigrainewithauraandoverall
and specific cardiovascular disease events differed
according to vascular risk status, as measured by the
Framingham risk score.
16
METHODS
Study population
We carried out a prospective cohort study among
participants in the women’s health study, a completed
trial designed to test the benefits and risks of low dose
aspirin and vitamin E in the primary prevention of
cardiovascular disease and cancer among apparently
healthy women. The design and results have been
described in detail previously.
1718 Briefly, 39876 US
female health professionals aged ≥45 at study entry
(1992-5) and without a history of cardiovascular
disease, cancer, or other major illnesses, were ran-
domly assigned to aspirin (100 mg on alternate days),
vitamin E (600 IU on alternate days), both active
agents,orbothplacebos.Baselineinformationwasself
reported and was collected by a mailed questionnaire
thataskedaboutmanycerebrovascularriskfactorsand
lifestyle variables. Twice in the first year and yearly
thereafter, participants were sent follow-up question-
naires asking about study outcomes, personal char-
acteristics, medical history, and health habits. For this
analysis, we included follow-up information from
study entry to 31 March 2007. As of this date, follow-
up was 97% complete.
Beforerandomisation,bloodsampleswerecollected
in tubes containing EDTA from 28345 participating
women and stored in vapour phase liquid nitrogen
(−170°C). Samples were analysed for lipids and
inflammatory biomarkers. Total cholesterol, high
density lipoprotein cholesterol, and directly obtained
low density lipoprotein cholesterol were assayed with
reagents from Roche Diagnostics (Basel, Switzerland)
andGenzyme(Cambridge,MA).Cholesterolanalyses
could be performed on 27939 of the blood samples.
Assessment of migraine
Onthebaselinequestionnaireparticipantswereasked:
“Haveyoueverhadmigraineheadaches?”and“Inthe
past year, have you had migraine headaches?” From
this information, we categorised women into “no
history of migraine” and “any history of migraine.”
We also distinguished between “active migraine,”
which included women with self reported migraine in
the year before they completed the baseline ques-
tionnaire, and “prior migraine,” which included
women who reported ever having had a migraine but
none in the year before they completed the ques-
tionnaire. Those participants who reported active
migraine were asked about migraine specific features.
In the women’s health study,
1119 we have previously
showngood agreementwith 1988International Head-
ache Society (IHS) criteria for migraine.
20 Specifically,
we showed that among those who provided a blood
sample and reported active migraine, over 83%
fulfilledallbutoneIHScriterion(code1.7,migrainous
disorder) and over 46% fulfilled all IHS criteria for
migraine (code 1.1 migraine without aura).
11
Participants who reported active migraine were
further asked whether they had an “aura or any
indication a migraine is coming.” Responses were
used to classify women who reported active migraine
into active migraine with aura and active migraine
without aura.
Framingham risk score
WeusedtheFraminghamriskscore,whichpredictsthe
10yearriskofcoronaryheartdisease,asdefinedbythe
National Cholesterol Education Program,
16 to classify
participating women into vascular risk classes. This
score assigns points for age, total cholesterol, high
density lipoprotein cholesterol, smoking, and systolic
blood pressure stratified by treatment for hyperten-
sion. The points for each individual component are
summed and categorised into groups of 10 year risk of
coronaryheartdiseaseof≤1%(≤12points),2-4%(13-16
points), 5-9% (17-19 points), and ≥10% (≥20 points), as
in a previous report of the women’s health study.
21
Outcome ascertainment
All participants were followed up for the occurrence
of a major ischaemic vascular event, a combined end
pointdefinedasthefirstofanyofnon-fatalischaemic
stroke, non-fatal myocardial infarction, or ischaemic
cardiovascular death. In addition, we evaluated any
first myocardial infarction, ischaemic stroke, coron-
ary revascularisation procedure, and angina. There
weretoofewcasesofcardiovasculardeathtoperform
meaningful stratified analyses. Medical records were
obtained for all reported cardiovascular end points
except angina and reviewed by an end points
committee of physicians. Stroke was confirmed if
theparticipanthadanewfocalneurologicaldeficitof
sudden onset that persisted for more than 24 hours
and was then classified as ischaemic, haemorrhagic,
or undefined, with excellent agreement between
observers.
22 For this report, we included only cases
of ischaemic stroke and censored participants with
other subtypes of stroke at the time of event. The
occurrenceofmyocardialinfarctionwasconfirmedif
symptoms met World Health Organization criteria
and if the event was associated with abnormal levels
of cardiac enzymes or abnormal results on electro-
cardiography. Cardiovascular deaths were con-
firmed by autopsy reports, death certificates,
medical records, and information obtained from
next of kin or family members.
Statistical analyses
Ofthe27939womenwithcompletedbloodassays,we
excluded 79 with missing information on migraine
status, 321 with missing information on Framingham
risk score, and 20 who reported angina before they
RESEARCH
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women free from cardiovascular disease or angina at
studyentryforthisanalysis.Wecomparedthebaseline
characteristics of participants, with respect to their
migraine status, using analysis of covariance for
continuous measurements adjusted for age. We used
directstandardisationtoadjustcategoricalvariablesfor
age in 5 year increments.
We used multinominal logistic regression models to
calculate prevalence odds ratios and 95% confidence
intervals of the association between migraine and
migraine aura status with Framingham risk score
categories, adjusting for age. We used age adjusted
Cox proportional hazards models to evaluate the
associationbetweenmigraineandmigraineaurastatus
with risks of incident cardiovascular disease or angina.
We ran stratified analyses on categories of predicted
10 year risk of coronary heart disease based on
Framingham risk score (≤1%, 2-4%, 5-9%, and ≥10%).
Inaddition,weranstratifiedanalysesoftheassociation
between migraine and the various outcomes for
individual components of the Framingham risk score
(age, systolic blood pressure, smoking, total choles-
terol, and high density lipoprotein cholesterol). All
analyses were performed with SAS version 9.1 (SAS,
Cary, NC); P values were two tailed and P<0.05 was
considered significant.
RESULTS
Of the 27519 participants, 5074 (18.4%) women
reported any history of migraine, and 3577 (13.0%)
reported active migraine (migraine in the year before
Table 1 |Ageadjustedbaselinecharacteristicsin27519womenaccordingtomigrainestatusinwomen’shealthstudy.Figuresarepercentages*ofwomenunless
statedotherwise
Characteristics No migraine history
Active migraine with
aura
Active migraine
without aura Prior migraine† P value‡
No of participants 22 445 1418 2159 1497
Mean (SE) age (years) 54.9 (0.05) 53.2 (0.19) 52.6 (0.15) 55.5 (0.18) <0.001
Mean (SE) Framingham risk score 12.2 (0.02) 12.3 (0.09) 12.3 (0.07) 12.7 (0.08) <0.001
Framingham estimate of 10 year risk of coronary heart disease:
≤1 54.4 53.6 54.3 48.9
<0.001
2-4 30.4 30.3 30.8 32.3
5-9 11.4 11.8 11.5 13.2
≥10 3.9 4.3 3.5 5.6
Mean (SE) total cholesterol (mmol/l) 5.46 (0.002) 5.52 (0.03) 5.51 (0.02) 5.56 (0.03) 0.001
Mean (SE) HDL cholesterol (mmol/l) 1.39 (0.003) 1.37 (0.01) 1.38 (0.008) 1.36 (0.01) 0.001
Mean (SE) systolic blood pressure (mm Hg) 123.6 (0.09) 123.5 (0.35) 124.4 (0.29) 124.6 (0.34) 0.001
Smoking:
Never 51.2 52.4 56.2 50.5
0.03 Past 37.0 37.3 34.5 35.5
Current 11.8 10.3 9.3 14.1
History of hypertension§ 24.7 25.6 26.1 30.5 <0.001
History of diabetes 2.5 1.8 1.6 2.6 0.23
Mean (SE) BMI 25.9 (0.03) 25.8 (0.13) 26.2 (0.11) 26.1 (0.13) 0.02
Alcohol consumption:
Rarely/never 43.5 48.2 47.4 45.1
<0.001
1-3 drinks/month 13.1 12.9 15.4 14.3
1-6 drinks/week 32.7 30.5 30.0 30.4
≥1 drink/day 10.8 8.4 7.2 10.3
Physical activity:
Rarely/never 36.9 38.0 39.4 39.2
<0.001
<1/week 19.2 20.4 21.7 20.2
1-3/week 32.3 30.9 29.3 29.4
≥4/week 11.6 10.7 9.7 11.2
Hormone therapy after menopause:
Never 49.4 38.7 44.7 46.0
<0.001 Past 8.7 10.2 8.5 10.2
Current 41.9 51.2 46.7 43.8
Family history of myocardial infarction before age 60 12.6 14.4 13.0 14.0 0.09
SE=standard error; HDL=high density lipoprotein; BMI=body mass index.
*Proportions might not add up to 100% because of rounding or missing values.
†Women who indicated history of migraine but no active migraine in year before completing baseline questionnaire.
‡From analysis of covariance for continuous variable or Mantel-Haenszel test for categorical variables.
§Defined as previous diagnosis of hypertension, systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or receipt of blood pressure lowering treatment at baseline.
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reported migraine aura.
Table 1 summarises the association between base-
line characteristics according to migraine status.
Compared with women without a history of migraine,
women with active migraine with aura were younger,
less likely to consume alcohol, less likely to exercise
regularly, and more likely to currently use hormone
therapy after the menopause. Women with prior
migraine tended to have raised total cholesterol
concentration and were more likely to currently
smoke cigarettes, have higher systolic blood pressure,
and to have a history of hypertension compared with
theothermigrainegroups.Meanconcentrationofhigh
density lipoprotein cholesterol was higher among
women without a history of migraine. Family history
of myocardial infarction was equally distributed
among the migraine groups.
With regard to categories of the Framingham risk
score, women who reported any history of migraine
weremorelikelytohaveahigherpredicted10yearrisk
of coronary heart disease. Compared with women
withoutahistoryofmigraineandlowestimatedriskfor
coronary heart disease (≤1%), the age adjusted odds
ratio of a predicted 10 year risk of coronary heart
diseaseof≥10%was1.26(95%confidenceinterval1.06
to 1.49) for women who reported any history of
migraine.Afterfurtherstratification,thisincreasedrisk
was apparent only in the group of migraineurs who
indicated prior migraine (history of migraine but not
active migraine) (1.83, 1.43 to 2.35) (table 2).
During a mean of 11.9 years of follow-up (326547
person years), 697 participants had a first major
ischaemic cardiovascular disease event, which, taking
intoaccountthepotentialformultipleeventsinasingle
individual, included 306 first ischaemic strokes, 301
first myocardial infarctions, and 148 deaths from
cardiovascular disease. In addition, 647 underwent
coronary revascularisation, and 412 reported angina
during follow-up. The risk of major cardiovascular
disease increased with increasing Framingham risk
score.Comparedwithwomenwithapredicted10year
risk of coronary heart disease of ≤1%, the age adjusted
hazard ratios for major cardiovascular disease were
3.11 (2.46 to 3.93), 6.04 (4.67 to 7.81), and 10.40 (7.76
to13.94)forwomenwithpredictedrisksof2-4%,5-9%,
and ≥10%, respectively.
Activemigrainewithaurawasassociatedwithabout
a twofold increased risk of major cardiovascular
disease, ischaemic stroke, and myocardial infarction
(table 3).AfterstratificationbyFraminghamriskscore
groups, the pattern of association between active
migraine with aura and major cardiovascular disease
was U shaped, with the highest estimate in the lowest
risk score group. We observed a strikingly different
pattern of association for the outcomes of ischaemic
stroke and myocardial infarction (table 3, figure).
Compared with women without a history of migraine,
theageadjustedhazardratiosforischaemicstrokewere
3.88 (1.87 to 8.08) in the lowest risk score group and
1.00 (0.24 to 4.14) for the highest. For myocardial
infarction, these estimates were 1.29 (0.40 to 4.21) and
3.34 (1.50 to 7.46), respectively.
Table2 |Ageadjustedassociation(oddsratio)*betweenmigraineandFraminghampredicted10yearriskofcoronaryheartdiseasein27519womeninwomen’shealth
study
Framingham estimate of 10 year risk of coronary heart disease
No of women
in category
≤1%
2-4% 5-9% ≥10%
No of
women
OR
(95% CI) P value
No of
women
OR
(95% CI) P value
No of
women
OR
(95% CI) P value
No history of migraine
(n=22 445)
12 000 6912 1.00 (reference) — 2632 1.00 (reference) — 901 1.00 (reference) —
History of migraine:
Any (n=5074) 2862 1487 1.09(1.01to1.17) 0.03 535 1.15(1.03to1.29) 0.02 190 1.26(1.06to1.49) 0.009
Active migraine with
aura (n=1418)
840 393 1.02(0.89to1.17) 0.76 141 1.14(0.94to1.40) 0.19 44 1.14(0.82to1.59) 0.42
Active migraine
without aura (n=2159)
1332 595 1.02(0.92to1.14) 0.72 178 1.00(0.84to1.20) 0.97 54 1.02(0.76to1.36) 0.92
Prior migraine†
(n=1497)
690 499 1.27(1.12to1.45) <0.01 216 1.46(1.22to1.75) <0.01 92 1.83(1.43to2.35) <0.01
*Calculated from multinominal logistic regression model with women without history of migraine and with Framingham estimated 10 year risk of coronary heart disease ≤1% as reference
group.
†Women with history of migraine but no active migraine in year before completing baseline questionnaire.
Framingham estimate of 10 year risk of coronary heart disease (%)
H
a
z
a
r
d
 
r
a
t
i
o
0-1
*
*
0
1
2
3
4
Ischaemic stroke * P<0.01
Myocardial infarction
2-4 5-9 >10
Age adjusted association between migraine with aura and
ischaemicstrokeandmyocardialinfarctionaccordingto10year
risk of coronary heart disease estimated by Framingham risk
score.Referencegroupwaswomenwithouthistoryofmigraine
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migraine with aura and coronary revascularisation,
the hazard ratios were 1.58 (0.80 to 3.14), 1.70 (1.03 to
2.79),0.93(0.46to1.90),and2.21(1.11to4.40)forrisk
scoregroups≤1%,2-4%,5-9%,and≥10%,respectively.
For angina, these estimates were 2.12 (1.01 to 4.45),
1.40(0.68to2.88),1.09(0.48to2.50),and2.06(0.82to
5.17).
When we evaluated the individual components of
the Framingham risk score, the association between
active migraine with aura and ischaemic stroke was
particularly apparent for the younger age groups (45-
54 and 55-64) and was not apparent among women
aged ≥65 (table 4). The risk was further increased for
womenaged45-49(5.35,2.08to13.79;P<0.001).With
regard to systolic blood pressure, we found a greater
risk of ischaemic stroke for women with low blood
pressure. This trend was further magnified among
women with systolic blood pressure <110 mm Hg
(5.18, 1.70 to 15.80; P<0.004). Furthermore, the
associated risk of ischaemic stroke for women with
active migraine with aura increased with decreasing
total cholesterol concentrations. When we evaluated
lower cholesterol concentrations, women with
migraine with aura and cholesterol <4.40 mmol/l had
furtherincreasedrisk(4.01,1.15to13.96,P=0.03).This
pattern was not driven by high density lipoprotein
cholesterol(table 4).TherewasaUshapedpatternwith
regard to smoking, showing increased risk for current
smokers and those who had never smoked, which
reached significance for those who had never smoked.
Table5summarisestheassociationbetweenmigraine
and myocardial infarction stratified by individual
componentsofthe Framinghamriskscore.The associa-
tion between active migraine with aura and myocardial
infarctionwas increased intheage groups 45-54 and55-
64. In contrast with ischaemic strokes, however, there
was nofurtherincreasedriskwhenweevaluatedthe age
group 45-49 (data not shown). With regard to systolic
bloodpressure,wefoundanincreasedriskofmyocardial
infarctionforwomenwithactivemigrainewithaurawho
had values <120 mm Hg and ≥140 mm Hg. While the
riskdidnotfurtherincreaseincategoriesabove140mm
Hg (data not shown), the associated risk of myocardial
infarctionwas strongestforwomenwithactive migraine
with aura who had a systolic blood pressure <110 mm
Hg (10.00, 2.96 to 33.77; P<0.001). In contrast with
ischaemic stroke, the association between active
migraine with aura and migraine with aura increased
with increasing total cholesterol concentrations. The
patternofassociationbetweenactivemigrainewithaura
and myocardial infarction according to category of
smokingwassimilartothefindingsforischaemicstroke.
DISCUSSION
Summary of findings
In this large prospective cohort of women, the associa-
tion between active migraine with aura and specific
Table 3 |Ageadjustedassociation(hazardratio)betweenmigraineandcardiovasculardisease,stratifiedbyFraminghamestimateof10yearriskofcoronaryheart
disease*in27519womeninwomen’shealthstudy
No history of
migraine (n=22
445)†
Active migraine with aura (n=1418) Active migraine without aura (n=2159) Prior migraine‡ (n=1497)
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
Major cardiovascular event§ § (n= =697)
Overall 557 53 1.93(1.45to2.56) <0.001 39 1.00(0.72to1.38) 0.98 48 1.23(0.92to1.66) 0.16
Framingham risk group:
≤1% 80 14 2.69(1.52to4.75) <0.001 9 1.09(0.55to2.18) 0.80 8 1.72(0.83to3.57) 0.14
2-4% 204 16 1.60(0.96to2.67) 0.07 18 1.22(0.75to1.99) 0.42 11 0.74(0.40to1.36) 0.33
5-9% 169 14 1.80(1.04to3.11) 0.04 9 0.87(0.45to1.71) 0.69 16 1.19(0.71to1.98) 0.51
≥10% 104 9 1.93(0.97to3.82) 0.06 3 0.52(0.17to1.66) 0.27 13 1.32(0.74to2.35) 0.35
Ischaemic stroke (n= =306)
Overall 251 22 1.80(1.16to2.79) 0.008 17 0.99(0.60to1.62) 0.97 16 0.91(0.55to1.50) 0.70
Framingham risk group:
≤1% 36 9 3.88(1.87to8.08) <0.001 4 1.09(0.39to3.07) 0.87 3 1.44(0.44to4.66) 0.55
2-4% 94 6 1.34(0.59to3.07) 0.48 9 1.39(0.70to2.77) 0.35 3 0.44(0.14to1.38) 0.16
5-9% 77 5 1.41(0.57to3.51) 0.46 2 0.43(0.11to1.75) 0.24 8 1.30(0.63to2.70) 0.48
≥10% 44 2 1.00(0.24to4.14) 0.99 2 0.96(0.23to4.00) 0.95 2 0.49(0.12to2.02) 0.32
Myocardial infarction (n= =301)
Overall 240 24 1.94(1.27to2.95) 0.002 17 0.95(0.58to1.56) 0.85 20 1.20(0.76to1.89) 0.44
Framingham risk group:
≤1% 35 3 1.29(0.40to4.21) 0.67 4 1.10(0.39to3.09) 0.86 3 1.48(0.45to4.80) 0.52
2-4% 83 8 1.87(0.90to3.88) 0.09 9 1.41(0.71to2.83) 0.33 5 0.83(0.34to2.04) 0.68
5-9% 79 6 1.58(0.69to3.65) 0.28 3 0.60(0.19to1.92) 0.39 6 0.94(0.41to2.16) 0.89
≥10% 43 7 3.34(1.50to7.46) 0.003 1 0.35(0.05to2.54) 0.30 6 1.36(0.58to3.20) 0.48
*Women in each risk group: 14 862 in ≤1%; 8399 in 2-4%; 3167 in 5-9%; 1091 in ≥10%.
†Hazard ratio=1.
‡History of migraine but no active migraine in year before completion of baseline questionnaire.
§Defined as first of any of: non-fatal ischaemic stroke, non-fatal myocardial infarction, or death from ischaemic cardiovascular cause.
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status according to Framingham risk score groups. The
association between active migraine with aura and
ischaemic stroke was apparent only among women in
the lowest Framingham risk score group, while the
association with myocardial infarction was apparent
onlyamongwomeninthehighestgroup.Withregardto
the individual components of the Framingham risk
score,thisdiametricpatternofassociationwasdrivenby
particularly increased risk of ischaemic stroke among
women with active migraine with aura who were young
( a g e d4 5 - 4 9 )a n dw h oh a dl o wt o t a lc h o l e s t e r o l
concentrations.Incontrast,womenwithactivemigraine
with aura who had high total cholesterol concentrations
had an increased risk of myocardial infarction. The
association between migraine with aura and coronary
revascularisation procedures was similar to the myo-
cardial infarction finding, while our data suggest a U
shaped association between migraine with aura and
angina according to the Framingham risk score.
We have previously shown that the association
between migraine with aura and cardiovascular disease
in the women’s health study remains significant even
after adjustment for major cardiovascular risk factors.
11
Thedatapresentedheresuggestthatamongwomenwith
migraine with aura, information on the underlying
vascular risk status can help to identify women who are
at particular increased risk for specific cardiovascular
disease events.
Our data add to the growing evidence that migraine
isassociatedwithincreasedriskofvascularevents
681112
and that the risk of specific cardiovascular disease
outcomes might depend on the presence or absence of
vascular risk factors.
58 Our results are of interest for
general practitioners as a history of migraine in
combination with information on vascular risk status,
as measured by the Framingham risk score, could
indicate future cardiovascular disease events. This is
analogous to recent work indicating that a history of
pre-eclampsiaisariskfactorforcardiovasculardisease
in later life.
23 Our data imply that among patients with
migraine, cardiovascular risk factors should be more
carefully sought and controlled.
Resultsofthegeneticepidemiology ofmigrainestudy
suggestthatmigraine,particularlymigraine withaura,is
associated with increased likelihood of an unfavourable
cardiovascular risk profile and a high Framingham risk
score.
13 Compared with participants without migraine
and predicted risk (according to the Framingham risk
score) for coronary heart disease of <1%, migraineurs
with aura had age and sex adjusted odds ratios of 1.84
(0.8 to 4.5) for predicted risk of 10-20%, and 4.01 (1.1 to
15.0) for predicted risk of ≥21%. While in our study any
history of migraine was also associated with increased
predicted 10 year risk of coronary heart disease
(according to the Framingham risk score), this associa-
tiondidnotdifferwithregardtomigraineaurastatus.We
hadtoofewparticipantswithveryhighFraminghamrisk
Table 4 |Ageadjustedassociation(hazardratio)betweenmigraineandischaemicstroke,stratifiedbycomponentsofFraminghamriskscorein27519womenin
women’shealthstudy
No history of
migraine
(n=22 445)*
Active migraine with aura (n=1418)
Active migraine without aura
(n=2159) Previous migraine† (n=1497)
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
Age (years):
45-54 (n=16 444) 64 12 2.59(1.40to4.80) 0.003 8 1.07(0.51to2.24) 0.85 2 0.51(0.12to2.07) 0.34
55-64 (n=8160) 91 9 2.13(1.07to4.23) 0.03 5 0.79(0.32to1.95) 0.61 8 1.19(0.58to2.46) 0.63
≥65 (n=2915) 96 1 0.32(0.04to2.29) 0.26 4 1.28(0.47to3.49) 0.63 6 0.85(0.37to1.93) 0.69
Systolic blood pressure (mm Hg):
<120 (n=12 389) 55 10 3.42(1.74to6.75) <0.001 3 0.69(0.22to2.22) 0.54 4 1.21(0.44to3.34) 0.71
120-139 (n=11 678) 102 6 1.18(0.52to2.69) 0.69 10 1.47(0.76to2.84) 0.25 7 0.93(0.43to2.00) 0.85
≥140 (n=3452) 94 6 1.49(0.65to3.42) 0.34 4 0.65(0.24to1.77) 0.40 5 0.67(0.27to1.65) 0.39
Smoking:
Never (n=14 219) 104 11 2.31(1.23to4.32) 0.009 8 1.12(0.54to2.32) 0.76 4 0.54(0.20to1.45) 0.22
Past (n=10 100) 98 6 1.23(0.54to2.82) 0.62 5 0.82(0.33to2.03) 0.67 6 0.89(0.39to2.04) 0.79
Current (n=3200) 49 5 2.10(0.84to5.30) 0.11 4 1.25(0.45to3.47) 0.67 6 1.63(0.70to3.81) 0.26
Total cholesterol (mmol/l):
<5.17 (n=11 171) 58 10 3.29(1.68to6.45) <0.001 9 2.18(1.07to4.44) 0.03 7 1.85(0.84to4.05) 0.12
5.17-6.20 (n=10 292) 106 5 1.08(0.44to2.65) 0.87 4 0.58(0.21to1.58) 0.29 4 0.58(0.21to1.57) 0.28
≥6.21 (n=6056) 87 7 1.56(0.72to3.38) 0.26 4 0.65(0.24to1.77) 0.39 5 0.69(0.28to1.70) 0.42
HDL cholesterol (mmol/l):
<1.03 (4762) 60 5 1.56(0.63to3.90) 0.34 7 1.55(0.70to3.42) 0.28 6 1.33(0.57to3.07) 0.51
1.03-1.54 (n=14 536) 121 13 2.19(1.23to3.89) 0.008 5 0.61(0.25to1.49) 0.28 7 0.81(0.38to1.74) 0.60
≥1.55 (n=8221) 70 4 1.27(0.46to3.48) 0.64 5 1.12(0.45to2.79) 0.81 3 0.61(0.19to1.95) 0.41
HDL=high density lipoprotein.
*Hazard ratio=1.
†History of migraine but no active migraine in year before completion of baseline questionnaire.
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between migraine and 10 year risk prediction for
coronary heart disease of ≥21%.
Potential biological mechanisms
Recent studies on the pathophysiology of migraine
suggest that migraine can also be viewed in part as a
systemic disorder that is affecting the vasculature, and
migraineursmighthavereducednumberandfunctionof
endothelial progenitor cells, a surrogate for marker for
impaired vascular function.
24 Even in the absence of
vascular risk factors, people with migraine have
decreased cerebral
25 and peripheral vascular
resistance
3 and increased likelihood of retinal micro-
vascular signs,
4 hypercoagulability,
26 and
inflammation.
27 Moreover, the altered vascular reactiv-
ityisalreadypresentamongyoungpatientswitharecent
onset of migraine (mean age 24.6).
3
Findingsfrompreviousstudieshavesuggestedthatthe
association between migraine with aura and ischaemic
stroke is more apparent forindividuals without vascular
risk factors
578with the exception of smoking and use of
oral contraceptives in women.
814 In particular, people
withmigraineandnohistoryofhypertensionordiabetes
had increased risk of ischaemic stroke.
58 People with
migraine also have a higher likelihood of retinal
microvascular signs.
4 Furthermore, the proportion of
ischaemic strokes among patients with migraine is less
likely to be of atherosclerotic origin,
78and, specifically,
ischaemic strokes in the posterior circulation of migrai-
neurs are probably caused by microembolism and
hypoperfusion.
28 The increased risk of ischaemic stroke
formigraineurswithaurainthelowestFraminghamrisk
score group seen in our study supports these findings.
Because the score is composed of traditional risk factors
for cardiovascular disease, it can be interpreted as a
proxy for vascular health. Thus, it is plausible that the
biological mechanisms by which migraine with aura
resultsinischaemicvasculareventsinthebrainrequirea
vasculature not altered by atherosclerosis but might
involve microvascular changes.
Several studies have found an association between
migraine with aura and angina but not myocardial
infarction.
910In addition, patients with active migraine
with chest symptoms or suspected coronary ischaemia
had lower angiographic coronary severity scores than
patientswithsimilarsymptomsbutnomigraine.
29Inour
data, the association between migraine with aura and
anginawasincreasedforpatientsinthelowandhighrisk
score groups. Furthermore, our data indicate that the
association between migraine with aura and myocardial
infarction is apparent only among patients with a high
Framinghamriskscore.Thus,theeffectofmigrainewith
aura on the coronary arteries might involve two
mechanisms, one involving a vasculature not altered
by atherosclerosisleadingtoanginaandoneinvolvinga
vasculature impaired by atherosclerosis leading to
angina and myocardial infarction. Moreover, as
Table 5 |Ageadjustedassociation(hazardratio)betweenmigraineandmyocardialinfarction,stratifiedbycomponentsofFraminghamriskscorein27519womenin
women’shealthstudy
No history of
migraine
(n=22 445)*
Active migraine with aura (n=1418)
Active migraine without aura
(n=2159) Previous migraine† (n=1497)
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
No of
women HR (95% CI) P value
Age (years):
45-54 (n=16 444) 65 10 2.10(1.08to4.09) 0.03 7 0.92 (0.42 to 2.00) 0.83 7 1.75(0.81to3.83) 0.16
55-64 (n=8160) 109 11 2.09(1.12to3.90) 0.02 9 1.16 (0.58 to 2.28) 0.68 5 0.62(0.25to1.52) 0.30
65 (n=2915) 66 3 1.39(0.44to4.42) 0.58 1 0.46 (0.06 to 3.28) 0.43 8 1.65(0.79to3.45) 0.18
Systolic blood pressure (mm Hg):
<120 (n=12 389) 38 7 3.53(1.57to7.95) 0.002 4 1.37 (0.48 to 3.84) 0.56 1 0.44(0.06to3.17) 0.41
120-139 (n=11 678) 135 10 1.33(0.70to2.53) 0.39 11 1.01 (0.54 to 1.87) 0.99 12 1.21(0.67to2.18) 0.54
≥140 (n=3452) 67 7 2.45(1.12to5.36) 0.03 2 0.45 (0.11 to 1.83) 0.26 7 1.34(0.61to2.91) 0.46
Smoking:
Never (n=14 219) 78 11 2.82(1.49to5.32) 0.001 7 1.16 (0.53 to 2.53) 0.71 9 1.64(0.82to3.27) 0.16
Past (10 100) 94 6 1.26(0.55to2.88) 0.59 7 1.16 (0.53 to 2.51) 0.71 5 0.78(0.32to1.91) 0.58
Current (n=3200) 68 7 2.08(0.95to4.55) 0.07 3 0.65 (0.20 to 2.06) 0.46 6 1.17(0.51to2.69) 0.72
Total cholesterol (mmol/l):
<5.17 (n=11 171) 61 4 1.24(0.45to3.41) 0.68 3 0.69 (0.21 to 2.20) 0.52 7 1.77(0.81to3.87) 0.15
5.17-6.20 (n=10 292) 90 7 1.54(0.71to3.34) 0.27 9 1.33 (0.66 to 2.65) 0.42 7 1.19(0.55to2.56) 0.66
≥6.21 (n=6056) 89 13 2.71(1.51to4.86) <0.001 5 0.73 (0.30 to 1.80 ) 0.49 6 0.82(0.36to1.89) 0.65
HDL cholesterol (mmol/l):
<1.03 (4762) 82 8 1.71(0.83to3.55) 0.15 8 1.14 (0.55 to 2.38) 0.72 8 1.27(0.62to2.63) 0.52
1.03-1.54 (n=14 536) 123 12 1.94(1.07to3.52) 0.03 8 0.93 (0.45 to 1.91) 0.85 7 0.81(0.38to1.72) 0.58
≥1.55 (n=8221) 35 4 2.44(0.86to6.88) 0.09 1 0.42 (0.06 to 3.11) 0.40 5 2.07(0.81to5.28) 0.13
HDL=high density lipoprotein.
*Hazard ratio=1.
†History of migraine but no active migraine in year before completion of baseline questionnaire.
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migraineatbaseline(thatis,themigrainehadstoppedor
thefrequencyofmigraineattackswaslessthanoneattack
ayear)hadastrongerassociationwithhighFramingham
r i s ks c o r ea n da r ea l s om o r el i k e l yt oh a v ei n c r e a s e d
levels of biomarkers of cardiovascular disease,
30 we
suggest that an impaired vasculature is involved in the
declining one year prevalence of migraine in older age
groups.
1 As our data do not allow us to directly test this
hypothesis, however, future research is warranted to
further evaluate potential biological mechanisms of the
association between migraine with aura and ischaemic
vascular events. Of particular interest is whether
continuingattacksofmigrainewithauraleadtochanges
in the peripheral vasculature, which increase the
susceptibility to atherosclerotic changes.
Strengths and weaknesses of study
Our study has several strengths, including the pro-
spective design, large number of participants and
outcome events, long follow-up and participation
rate, standardised evaluation of migraine and cardio-
vascular disease risk factors, confirmed cardiovascular
disease events by an end points committee of
physicians,andthehomogeneousnatureofthecohort,
which could reduce confounding.
Several limitations should be also considered when
interpreting our results. Firstly, migraine and migraine
aura status were self reported leading to potential
misclassification. Because of the prospective design,
however, any misclassification would probably result in
underestimation of relative risks and would be unlikely
to explain the observed association pattern. Further-
more, we have previously reported that our migraine
classification had good agreement with 1988 IHS
criteria
11 and our prevalence of migraine and migraine
aura is close to that reported in other population based
studies.
13132 Secondly, we had no detailed information
on use of specific drugs for migraine that might be
associated with ischaemic events. Such drugs, however,
tend to be used by all migraineurs, not just those with
migraine aura. Furthermore, the different pattern of
association between migraine with aura and ischaemic
stroke and myocardial infarction according to vascular
risk status canhardly beexplainedbydrug use. Thirdly,
despite the overall high number of outcome events, this
number was small when we stratified by migraine and
Framingham risk score categories. Fourthly, our strati-
fied analyses are adjusted only for age and not other
major cardiovascular disease risk factors. We have
previouslyshown,however,thattheassociationbetween
migraine with aura and cardiovascular disease in this
cohort is independent of major risk factors for cardio-
vascular disease.
11 In addition, inclusion of major risk
factors for cardiovascular disease as well as randomised
treatment assignments in the stratified models showed
similar associations (data not shown). Residual con-
founding remains a potential alternative explanation as
our data are observational. Finally, participants in the
women’shealthstudywere all healthprofessionals aged
≥45 and mostly white, thus generalisability might be
limited. We have no reason to believe that that the
biological mechanisms by which migraine with aura
might be associated with vascular events would be
different in other populations of women.
Conclusions
Results from this large prospective study of women
indicate that information on vascular risk status might
help to identify women with migraine with aura who
are at a particularly increased risk for specific future
cardiovascular disease events with a diametric pattern
of association for ischaemic stroke and myocardial
infarction. Physicians should consider evaluating
vascularriskfactorsinpatientswithmigrainewithaura.
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